- Home
- SPCE vs NTHI Comparison
SPCE vs NTHI Comparison
Compare SPCE & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPCE | NTHI |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 193.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPCE | NTHI |
|---|---|---|
| Price | $2.92 | $8.87 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.22 | N/A |
| AVG Volume (30 Days) | ★ 4.6M | 55.1K |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,661,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,528.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $3.20 |
| 52 Week High | $6.64 | $25.00 |
Technical Indicators
Market Signals| Indicator | SPCE | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 49.39 |
| Support Level | $2.98 | $8.51 |
| Resistance Level | $3.18 | $10.26 |
| Average True Range (ATR) | 0.18 | 0.80 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 10.64 | 38.85 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).